1. Home
  2. BOC vs ACRS Comparison

BOC vs ACRS Comparison

Compare BOC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$12.11

Market Cap

377.5M

Sector

N/A

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.51

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
ACRS
Founded
2009
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.5M
311.0M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
BOC
ACRS
Price
$12.11
$4.51
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$10.20
AVG Volume (30 Days)
139.3K
1.4M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
$114,376,348.00
$1,683,000.00
Revenue This Year
$5.79
N/A
Revenue Next Year
$4.76
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
5.64
N/A
52 Week Low
$11.03
$1.20
52 Week High
$15.60
$4.89

Technical Indicators

Market Signals
Indicator
BOC
ACRS
Relative Strength Index (RSI) 43.21 61.28
Support Level $11.88 $3.16
Resistance Level $12.61 $4.56
Average True Range (ATR) 0.26 0.23
MACD -0.03 0.01
Stochastic Oscillator 14.29 82.93

Price Performance

Historical Comparison
BOC
ACRS

About BOC Boston Omaha Corporation

Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: